Varex Imaging Corporation (VREX) witnessed a significant pre-market surge of 5.77% on Wednesday, following the release of its fourth-quarter earnings report and insights into the company's strategic growth initiatives.
The medical imaging technology provider reported strong performance in the industrial segment during the fourth quarter, with revenues exceeding guidance. Additionally, the company expressed optimism about the potential growth in medical imaging demand in China, positioning itself to capitalize on the market's recovery.
Notably, Varex Imaging is investing in photon counting technologies, which are expected to be a significant revenue growth driver. The company aims to generate $150 million in annual revenue from this advanced technology by fiscal 2029. Furthermore, Varex is expanding its product portfolio into premium applications such as surgery, oncology, and cardiology, fueling future growth prospects.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。